MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
– RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with…
From Phase III Trials to Commercialization Partnerships, MindRank’s AI Drug Development Value Comes into Focus
TMX Group Equity Financing Statistics – September 2026
TMX Group Limited Announces Release Date for Q3 2026 Financial Results and Analyst Conference Call
GMG Announces 48% Increase in Energy Density, Doubling of Cycle Life and 94% Energy Efficiency for 6 Minute Fast Charge
DGTL Holdings Inc. Announces Failure-to-File Cease Trade Order